PCVX - Vaxcyte Inc - Stock Price & Dividends

Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing innovative protein vaccines to combat bacterial infectious diseases.

The company's lead vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease. This vaccine has the potential to provide broad protection against pneumococcal infections, which can cause serious illnesses such as pneumonia, meningitis, and sepsis.

In addition to VAX-24, Vaxcyte is developing a pipeline of vaccine candidates to address emerging strains and antibiotic resistance. For example, VAX-31 is being developed to protect against emerging strains of pneumococcal bacteria, while VAX-A1 is a novel conjugate vaccine candidate aimed at preventing disease caused by Group A Streptococcus, a common cause of skin infections and other illnesses.

The company is also working on VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis, a common gum infection. Furthermore, Vaxcyte is developing VAX-GI, a vaccine candidate designed to prevent Shigella, a bacterial illness that can cause diarrhea, fever, and abdominal pain.

Formerly known as SutroVax, Inc., the company changed its name to Vaxcyte, Inc. in May 2020. Founded in 2013, Vaxcyte is headquartered in San Carlos, California, and is committed to developing innovative vaccines to improve public health. For more information, visit their website at https://vaxcyte.com.